<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A9770164-A5A6-4636-AAC3-260D824A433B"><gtr:id>A9770164-A5A6-4636-AAC3-260D824A433B</gtr:id><gtr:name>Ctr for Applied Microbiological Res CAMR</gtr:name><gtr:department>Cell Culture</gtr:department><gtr:address><gtr:line1>Research (CAMR)</gtr:line1><gtr:line2>Porton Down</gtr:line2><gtr:line4>Salisbury</gtr:line4><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A9770164-A5A6-4636-AAC3-260D824A433B"><gtr:id>A9770164-A5A6-4636-AAC3-260D824A433B</gtr:id><gtr:name>Ctr for Applied Microbiological Res CAMR</gtr:name><gtr:address><gtr:line1>Research (CAMR)</gtr:line1><gtr:line2>Porton Down</gtr:line2><gtr:line4>Salisbury</gtr:line4><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0E06FCCC-FF86-4F6E-AC15-72F426311EA2"><gtr:id>0E06FCCC-FF86-4F6E-AC15-72F426311EA2</gtr:id><gtr:firstName>Bryan</gtr:firstName><gtr:surname>Bolton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/485337B5-FA1E-42B1-94C4-365DCADBC1C6"><gtr:id>485337B5-FA1E-42B1-94C4-365DCADBC1C6</gtr:id><gtr:firstName>Philippa</gtr:firstName><gtr:surname>Bracegirdle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BB440D9D-19FD-47E8-9F9D-5D0F7899E02B"><gtr:id>BB440D9D-19FD-47E8-9F9D-5D0F7899E02B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Lewis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9703548"><gtr:id>661FD463-F516-4B1F-8F8C-0CE7F9D73843</gtr:id><gtr:title>Application for Strategic Support for ECACC Human Cell Bank</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9703548</gtr:grantReference><gtr:abstractText>The ECACC Human Genetic Cell Bank is a service provider to the UK research effort into genetic disease. Its function is to preserve and secure irreplaceable human genomic material and ensure its availability in perpetuity if required. The material that ECACC makes available will be used to improve our knowledge of the genetic causes of disease. This knowledge will be used to improve the diagnosis and treatment of such diseases.

ECACC has its own website that describes all its activities, and actively promotes itself at sicentific meetings and by customer mailing.

CAMR will be administered by the newly formed Health Protection Agency (HPA), effective from April 2003, and ECACC will participate in the policies of that organisation for communication with the public. A description of ECACC activities is included in the CAMR Annual Report, which is widely circulated.

Finally, as partner to the MRC DNA Bank, ECACC will be included in the educational and public information policies of this organisation.</gtr:abstractText><gtr:technicalSummary>The existing grant, that this proposal intends to replace, is intended to enable a subsidised EBV transformation and banking service to a large number of relatively small HGMP projects. The number of such projects is declining, to be replaced by new projects, which are fewer in number but much larger often-involving thousands of samples. The whole apparatus for approving and subsidising small human genomic projects is increasingly inappropriate. Therefore we propose to consolidate the arrangement, already well established for the more recently MRC funded genomic projects, whereby direct costs of PBL and/or EBV transformation are charged directly to the end user. Funding requested in this grant is primarily concerned with infrastructure, and those generic costs that cannot easily be related to individual depositors.
The pivotal element of the ECACC Human Genetic Cell Bank, and related service operations, is the cryostored inventory. This is already large as a result of the HGMP projects and is now expanding at 2-3 times the rate of 1-2 years ago. MRC-funded stock now comprises almost 50% of our total inventory, and rising. It is in recognition of this trend that ECACC/CAMR invested in a new, state-of-the-art cryostore that was commissioned last Summer. Therefore this application requests funding to cover:
- the direct costs of maintaining up to 10 (25,000 ampoule capacity) liquid nitrogen cryostorage vessels representing in excess of 60,000 individuals. 
- Securing the inventory by introducing a new inventory control system combined with a full inventory stock check.
- Fund key staff to maintain continuity of expertise in order to be able to respond more easily to fluctuations in demand for the EBV transformation service.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2419864</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G9703548</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>